Asset profile
IO-202
Monoclonal antibody
Evidence outlook · lead readout
NCT04372433 · AML With Monocytic Differentiation, CMML
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT04372433: This was a non-randomized, open-label, single-arm dose-escalation study with no placebo or control group, and it measured only safety and tolerability. Results have not yet been reported.
Response rates are from the HMA-naive CMML expansion cohort of this study rather than the full treated population.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.